<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Access to Advanced Health Institute 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=51034></link><description><![CDATA[Access to Advanced Health Institute 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sun, 31 May 2026 13:10:20 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2026/05/12_31017998_20260531112646_9476388910.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[AAHI’s SLA-SE Adjuvant Technology Powers Lilly’s Acquisition of Curevo’s Next-Generation Shingles Vaccine]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1035577</link><description><![CDATA[SEATTLE--(Business Wire/Korea Newswire)--The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, today congratulates Eli Lilly and Company and Curevo Vaccine on Lilly’s acquisition of Curevo.  Curevo’s lead asset, amezosvatein (CRV-101), is a Phase 3-ready subunit vaccine for the prevention of...]]></description><pubDate>Sun, 31 May 2026 11:40:00 +0900</pubDate></item><item><title><![CDATA[AAHI의 SLA-SE 면역증강제 기술, 릴리가 인수한 큐레보 차세대 대상포진 백신 지원]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1035578</link><description><![CDATA[시애틀--(Business Wire/뉴스와이어)--글로벌 보건을 위한 백신 및 기술 개발에 전념하는 비영리 생명공학 조직인 액세스 투 어드밴스드 헬스 인스티튜트(Access to Advanced Health Institute, AAHI)는 일라이 릴리 앤 컴퍼니(Eli Lilly and Company)의 큐레보 백신(Curevo Vaccine) 인수에 대해 릴리와 큐레보에게 축하의 메시지를 전했다.  큐레보의 대표 자산인 아메조스바테인(amezosvatein)(CRV-101)은 대...]]></description><pubDate>Sun, 31 May 2026 11:40:00 +0900</pubDate></item></channel></rss>